• Study of Lyophilized Plasma Compared to Standard Fluid Solutions for Patients with Hemorrhagic Shock in the Emergency Room

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Austria
  • Testing the Safety and Effectiveness of CTH120 Compared to Placebo in Adult Men with Fragile X Syndrome

    Recruiting

    2 1
    Investigated Diseases:
    Spain
  • A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

    Recruiting

    3 1 1
    Investigated Drugs:
    Spain
  • A Study of Inavolisib for Patients with Advanced Endometrial Cancer Who Have PIK3CA Gene Mutations

    Recruiting

    2 1 1
    Investigated Drugs:
    Italy
  • Long-term Safety Study of ORX750 for Patients with Narcolepsy and Idiopathic Hypersomnia Who Completed a Previous ORX750 Trial

    Recruiting

    4 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Spain
  • Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

    Recruiting

    3 1 1 1
    Belgium France Spain
  • Testing a Pharmacogenetic-Guided Treatment Selection Strategy with Antidepressant Drug Combination for Patients with Depressive Disorder

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Spain
  • A Study of Autologous Urothelial Cell Treatment with Bioprinter During Bladder Reconstruction Surgery in Patients with Muscle-Invasive Bladder Cancer

    Recruiting

    1 1 1
    Investigated Drugs:
    Greece
  • A Study of Ferric Carboxymaltose to Improve Exercise Ability in Patients with Pulmonary Hypertension and Iron Deficiency

    Recruiting

    3 1 1
    Investigated Diseases:
    Belgium
  • Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

    Recruiting

    3 1
    Investigated Drugs:
    Austria Belgium Bulgaria Czechia Denmark France +11

powered by